pharm: 10-1 Nitric Oxide Flashcards
A: In what Physical state (solid vs liquid vs gas) does Nitric Oxide typically work?
B: Molecularly, From What and how is NO created?
C: Name the 2 Ways NO is generated in the body
D: NO is also known as ____
A: Gaseous (NO is a gaseous signaling molecule)
B: Oxidation of an [Arginine guanidine group] by [Nitric Oxide Synthase]
C:
1) Exposure to [bacterial LPS-B] / [bacterial endotoxin] β> Macrophage upregulation of iNOS2 β> Nitric Oxide Secretion
2) [ACh and Carbochol] can stimulate vasulcar endothelium to secrete NO
D: AKA EDRF [Endothelin Derived Growth Factor]
There are 3 Isoforms of [Nitric Oxide Synthase - NOS]
Describe NOS 1
A: Other Name
B: Tissue
C: Expression
D: Ca+ requirement?
E: Chromosome
(nNOS1)
A: [Neuronal NOS - 1]
B: Enables Neuronal epithelium to produce NO
C: [Constitutive Housekeeper]
D: YES, DOES REQUIRE Ca+
E: Chromo 12
There are 3 Isoforms of [Nitric Oxide Synthase - NOS]
Describe NOS 2
A: Other Name
B: Tissue
C: Expression (2)
D: Ca+ requirement?
E: Chromosome
F: Relation to Bacteria
(iNOS2)
A: [Inducible NOS - 2]
B: [Macrophage and Smooth Muscle cells]
C: [Transcriptional Induction]
D: No
E: Chromo 17
F: iNOS2 is bad because it is induced by [Bacterial LPS-B]
There are 3 Isoforms of [Nitric Oxide Synthase - NOS]
Describe NOS 3
A: Other Name
B: Tissue
C: Expression
D: Ca+ requirement?
E: Chromosome
F: How does eNOS3 contribute pathologically? (2)
(eNOS3)
A: [Endothelial NOS - 3]
B: Peripheral Endothelial Cells
C: [Constitutive Housekeeper]
D: No
E: Chromo 7
F: Involved in vasodilation during [acute inflammation] AND [Inflammation Diseases]β> allows NO to promote edema
A: How do you inhibit NO synthesis (5)?
B: [Nitric Oxide Synthase] isoforms are _____that contain ____ and require what to function?
C: Describe NO [Mechanism of Action]
D: Most NOS inhibitors are ______ analogues
βUse a [Free HAND] to inactivate NOβ
A:
- Arginine analogues inhibit conversion of [L-arginine] to [L-citrulline].
- Heme (NO scavenger)
- [Free Radical Superoxides] (which can also combine with NO to form [peroxynitrite ONOO]. [peroxynitrite ONOOβ] IS TOXIC and regulated by [glutathione which DEC in DM and CVD].
- NO Scavengers
- Direct Inhibitors of NOS or [NOS-to-arginine binding]
B: [Nitric Oxide Synthase] isoforms are Flavoproteins that contain HEME and require Co-FActors to function
C: NO interacts with [Heme moiety of soluble guanyl cylclase] β>causes it to convert GTP into cGMP. cGMP removes phosphate from [Myosin light chain]β> VasoRelaxation
D: Most NO inhibitors are [Arginine SUBSTRATE] analogues
A: NO undergoes oxidation AND reductive rxns β> ________
B: What is the Function of Nitrous Oxide?
C: Function of NiTrite?
D: Function of [Nitric Oxide] (4)?
A: NO undergoes oxidation AND reductive rxns β> Variety of Oxides of Nitrogen
B: Anesthetic
C: Stable Oxidation product of NO that decomposes to NO at an acidic pH
D: NO: Vasodilator / Platelet inhibitor / Immune regulator / neurotransmitter
A: Most NO inhibitors are ______ analogues
B: Name the 5 NO inhbiitors- ______ analogues
C: Which one inhibits iNOS2 dimerization? How does it work with the other 2 isomers?
D: Which is a [NO scavenger]?
A: Most NO inhibitors are [Arginine SUBSTRATE] analogues
B: L-NMMA / L-NAME / [7-Nitroindazole] / BBS2 / Hgb
C: BBS2 - and weakly works on [nNOS1 and eNOS3]
D: Hgb
A: NO can generate several reactive nitrogen derivatives by interacting with ______ and ______
B: How are these compounds bad for the body?
NO can generate [reactive nitrogen derivatives] by interacting with [molecular oxygen] and [Free superoxide radicals]
B: These RND oxides of nitrogen are highly reactive / unstable, interact with numerous proteins, lipids, [nucleic acids] and metabolize. They alter physiology of cells and tissues and mediate pathologic effects
A: 5 PROS/Indications of Nitric Oxide
B: 3 Cons of Nitric Oxide
PROS: β PAPAβS D is a PRO with Nitric Oxideβ
- [Broncho / VasoDilation] via smooth m. relaxation
- Immune Regulation (inhibits [WBC E-selectin] from adhesing to endotheliumβ>reduces ischemic/reperfusion injury)
- Anesthetic
- [Atherosclerosis Prevention and Tx]
- Pulmonary HTN
- Pediatric Acute Respiratory Distress Syndrome - PARDS
- [Stroke and Vascular Dementia] as a NTS and receptor neuromodulator
CONS:
- [Free Radical Formation]
- Nitrosation
- Irritant Effects
A: How does NO prevent Atherosclerosis (3)
B: How is NO related to [Graft Atherosclerosis]
B2: Whatβs the Catch 22 with this
- potent inhibitor of platelet [adhesion, activation, aggregation]
- regulates release of [serotonin, (Platelet Derived growth factors), thromboxane] from platelets
- Indircectly enhances Fibrinolysis by inhibiting antiplasmin release from platelets
B: [Graft Atherosclerosis] occurs after organ transplant and is a major cause of graft failure. [NO AND (Dietary L-Arginine) prevents Platelet activationβ> Reduce [Graft Atherosclerosis].
B2: Catch 22 = EXCESSIVE NOβ>Actually Promotes [Graft Atherosclerosis]
A: What does NANC neurons stand for?
B: Where are they and what are they used for?
A:[NANC neurons] = [Nonadrenergic, noncholinergic neurons].
B: Found in peripheral tissues and mediate Erectile response by releasing NO
A: Which Nitrate Drug is Ultra Short acting and rarely prescribed?
B: Duration of Action for Sublingual NTG
C: How is NO administered for [Primary Pulmonary HTN]
C2: Name 4 other indications for this type of NO administration
A: [Inhaled Amyl Nitrate]: DOA= 3-5 min
B: Sublingual NTG: DOA= 10-30 min
C: Administered in a Close Fitted Mask and then gradually tapered off to avoid rebound
C2:
- [INC Oxygenation in Newborn pulmonary hypOtension]
- Lung Transplant / Sickle Cell Crisis / [Cardiopulmonary bypass]
A: What is INOMAX and whatβs itβs indication?
B: NTG is _____ (route of administration) and used for _______
C: MOA / Route of Admin / Indication / Side Effects(4) for Hydralazine
A: INOMAX = Inhaled Nitric Oxide for Acute Coronary Syndrome
B: NTG is sublingual and used for [Pulmonary Arterial HTN]
C: Hydralazine: [NO donor] administered orally for HTN. Side Effects= HA / N/V / hypOtension
[Dietary L-Arginine]
A: MOA
B: Route of Administration
C: Indications (2)
D: Side Effects
A: NO Donor
B: Oral
C: ACS / Vascular Dz
D: hypOtension